Adjuvant Therapy of Stage IIIb Melanoma with Interferon Alfa-2b: Clinical and Immunological Relevance

Doveil, Gc; Fierro, Maria Teresa; Novelli, Mauro; Appino, A; Bertero, Maria Tiziana; Quaglino, Pietro; Bernengo, Mg

doi:10.1159/000246551

Cited by 10 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with this observation are the data recently published relative to Stage IIIB melanoma patients (according to the M. D. Anderson Cancer Center Classification), who were treated with IFN‐α as adjuvant therapy after the removal of metastatic lesions. These data show a clear improvement in the prognosis of treated patients 28, 29…”

Section: Discussionsupporting

confidence: 59%

“…The first regimens with IFN‐α as adjuvant therapy employed high and intermittent doses,15, 20‐22 whereas the current trend is to test lower doses of IFN‐α, which should be best tolerated by patients. Currently, there are different trials on the best course of adjuvant therapy for high risk melanoma employing IFN‐α, meant to establish the ideal scheme of treatment and the subgroups of patients who might benefit most from an adjuvant therapy 17, 28‐30…”

Section: American Joint Committee On Cancer Staging System (1992)mentioning

confidence: 99%

See 1 more Smart Citation

Postsurgical adjuvant therapy for melanoma

Rusciani

Petraglia

Alotto

et al. 1997

Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 59%

Section: American Joint Committee On Cancer Staging System (1992)mentioning

confidence: 99%

Postsurgical adjuvant therapy for melanoma

Rusciani

Petraglia

Alotto

et al. 1997

Cancer

View full text Add to dashboard Cite

show abstract

“…Several trials looked at the role of IFN-α in the adjuvant setting for melanoma patients at high risk for relapse, including patients with deep primary lesions and those with lymph node involvement [111][112][113][114][115][116]. Studies using relatively low doses of IFN (3 × 10 6 U tiw) failed to show an overall survival benefit in this patient group.…”

Section: Adjuvant Therapymentioning

confidence: 99%

Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities

2001

View full text Add to dashboard Cite

For the past 40 years, various forms of interferon (IFN) have been evaluated as therapy in a number of malignant and non-malignant diseases. With the advent of gene cloning, large quantities of pure IFN became available for clinical study. This paper reviews the biology, pharmacology, and clinical applications of IFN formulations most commonly used in oncology. It then reviews the most common side effects seen in patients treated with IFN, and makes recommendations for the management of IFN-induced toxicity.The major oncological indications for IFN include melanoma, renal cell carcinoma, AIDS-related Kaposi's sarcoma, follicular lymphoma, hairy cell leukemia, and chronic myelogenous leukemia. Unfortunately, IFN therapy is associated with significant toxicity, which can be divided into constitutional, neuropsychiatric, hematologic, and hepatic effects. These toxicities have a major impact on the patient's quality of life, and on the physician's ability to optimally treat the patient. Careful attention to all aspects of patient care can result in improved tolerability of this difficult but promising therapy. Conclusion: a better understanding of IFN biology, indications, side effect profiles, and toxicity management will aid in optimizing its use in the treatment of patients with cancer. The Oncologist 2001;6:34-55

show abstract

“…When metastases were detected in the course of followup, they were removed surgically and the therapy was continued, in line with studies of AJCC stage IIIA and IIIB patients [46,47].…”

Section: Methodsmentioning

confidence: 84%

Recombinant interferon α-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-α and 5-year follow-up

et al. 2007

View full text Add to dashboard Cite

Early surgical intervention remains the most successful therapy for melanoma. Despite better outcomes observed in soft tissue and lymph node metastases, the results of pharmacological therapies are still disappointing. Currently, there is no standard adjuvant therapy for melanoma. Low concentrations of coenzyme Q10 have been demonstrated in melanoma cell lines and in sera of melanoma patients. These data and the results of clinical trials of patients with other advanced cancers prompted this study of the long-term administration of an optimized dose of recombinant interferon alpha-2b and coenzyme Q10 to patients with stage I and II melanoma. A 3-year trial envisaging uninterrupted treatment with low-dose recombinant interferon alpha-2b (9 000 000 000 IU weekly) administered twice daily and coenzyme Q10 (400 mg/day) was conducted in patients with stage I and II melanoma (American Joint Committee on Cancer criteria 2002) and surgically removed lesions. Treatment efficacy was evaluated as incidence of recurrences at 5 years. All patients completed the treatment and the follow-up. Significantly different rates of disease progression were observed in the interferon+coenzyme Q10 and the interferon group for both stages. No patient withdrew from the study owing to side effects. Long-term administration of an optimized dose of recombinant interferon alpha-2b in combination with coenzyme Q10 seemed to induce significantly decreased rates of recurrence and had negligible adverse effects. A survival study could not be undertaken owing to the small patient sample and the short duration of follow-up.

show abstract

Adjuvant Therapy of Stage IIIb Melanoma with Interferon Alfa-2b: Clinical and Immunological Relevance

Cited by 10 publications

References 10 publications

Postsurgical adjuvant therapy for melanoma

Postsurgical adjuvant therapy for melanoma

Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities

Recombinant interferon α-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-α and 5-year follow-up

Contact Info

Product

Resources

About